
    
      PRIMARY OBJECTIVE:

      I. Assess the effects on quality of life (QOL) when supplementing zinc in upper
      gastrointestinal (GI) cancer patients while they are receiving chemotherapy.

      SECONDARY OBJECTIVES:

      I. Correlate hypoalbuminemia with serum zinc deficiency.

      II. Correlate zinc deficiency with neutropenia.

      OUTLINE: Patients are randomized into 1 of 2 groups.

      GROUP I: Patients receive zinc orally (PO) thrice daily (TID) for months 1 and 2 only of the
      first 4 months on therapy.

      GROUP II: Patients receive zinc orally (PO) TID for months 3 and 4 only of the first 4 months
      on therapy.
    
  